KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Raw Materials: 2023-2025

Historic Raw Materials for Aurinia Pharmaceuticals (AUPH) over the last 1 years, with Sep 2025 value amounting to $771,000.

  • Aurinia Pharmaceuticals' Raw Materials was N/A to $771,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $771,000, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2024, which is 2.52% down from last year.
  • Aurinia Pharmaceuticals' Raw Materials amounted to $771,000 in Q3 2025, which was down 0.00% from $771,000 recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Raw Materials' 5-year high stood at $1.7 million during Q4 2023, with a 5-year trough of $771,000 in Q1 2025.
  • For the 3-year period, Aurinia Pharmaceuticals' Raw Materials averaged around $1.2 million, with its median value being $771,000 (2025).
  • Data for Aurinia Pharmaceuticals' Raw Materials shows a maximum YoY declined of 2.52% (in 2024) over the last 5 years.
  • Aurinia Pharmaceuticals' Raw Materials (Quarterly) stood at $1.7 million in 2023, then decreased by 2.52% to $1.7 million in 2024, then reached $771,000 in 2025.
  • Its Raw Materials was $771,000 in Q3 2025, compared to $771,000 in Q2 2025 and $771,000 in Q1 2025.